The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Cadraten     ethylN-[[6-(ethyl-(2- hydroxypropyl)amino)...

Synonyms: Cadrilan, Cadralazina, cadralazine, Cadralazinum, SureCN48939, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of DC-826

  • Forearm venous tone and brachial artery hemodynamics, including determinations of the arterial diameter and compliance by the use of pulsed Doppler systems, were measured in 16 patients with sustained essential hypertension before and after acute oral cadralazine dosing [1].
  • The objective of this study was to investigate the effect of cadralazine in patients who had previously had hydralazine-induced lupus [2].
  • Cadralazine for the treatment of preeclampsia. An open, noncomparative, dose-finding pilot study [3].
  • Manifestations of the drug's vasodilating properties such as headache, asthenia, dizziness, palpitations and flushing are the most commonly reported symptoms during cadralazine monotherapy, but these may be reduced during combination therapy [4].
  • The hemodynamic study in responders showed that both cadralazine and chlorthalidone acted through a reduction of peripheral resistances without inducing reflex tachycardia [5].
 

High impact information on DC-826

 

Chemical compound and disease context of DC-826

 

Biological context of DC-826

 

Anatomical context of DC-826

  • These results suggest that cadralazine is metabolized to ISF-2405 and inhibits vascular smooth muscle contraction by inhibiting receptor-mediated Ca2+ influx, Ca2+ release and Ca2+ sensitization of contractile elements [14].
  • These findings substantiate the assumption that the slow onset and long duration of the pharmacological effect of cadralazine is closely related to the distribution pattern of the active metabolite ISF-2405 in blood vessels, a target tissue of antihypertensive vasodilator drugs [15].
  • Role of an intact endothelium in the vascular action of cadralazine and ISF2405 [16].
  • Cadralazine, which was positive in the drug lymphocyte stimulation test (DLST), could not be excluded from the causative drugs [17].
  • Interestingly, pharmacokinetic studies on cadralazine (a 3-hydrazinopyridazine protected as ethoxycarbonyl derivative) support the attractive hypothesis that the pro-drug is biotransformed topically to the active metabolite in the endothelium of arterial vessels, close to the site at which smooth muscle relaxation is required [18].
 

Associations of DC-826 with other chemical compounds

 

Gene context of DC-826

 

Analytical, diagnostic and therapeutic context of DC-826

References

  1. Effect of cadralazine on brachial artery hemodynamics and forearm venous tone in essential hypertension. Bouthier, J.A., Safar, M.E., Curien, N.D., London, G.M., Levenson, J.A., Simon, A.C. Clin. Pharmacol. Ther. (1986) [Pubmed]
  2. Cadralazine challenge in patients with previous hydralazine-induced lupus: a 6-month study. Pålsson, L., Weiner, L., Englund, G., Henning, M. Clin. Pharmacol. Ther. (1989) [Pubmed]
  3. Cadralazine for the treatment of preeclampsia. An open, noncomparative, dose-finding pilot study. Voto, L.S., Lapidus, A.M., Catuzzi, P., Uranga Imaz, F., Zin, C., Margulies, M. Hypertension (1992) [Pubmed]
  4. Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. McTavish, D., Young, R.A., Clissold, S.P. Drugs (1990) [Pubmed]
  5. Hemodynamic effects of cadralazine or chlorthalidone in verapamil-treated elderly hypertensives. Antonicelli, R., Savonitto, S., Tomassini, P.F., Gambini, C., Sardina, M., Paciaroni, E. International journal of clinical pharmacology and therapeutics. (1994) [Pubmed]
  6. Hemodynamics of the carotid artery after vasodilation in essential hypertension. Laurent, S., Lacolley, P., London, G., Safar, M. Hypertension (1988) [Pubmed]
  7. Controlled clinical trial of cadralazine as a second-step drug in the treatment of hypertension. Catalano, M., Parini, J., Romano, M., Libretti, A. Eur. J. Clin. Pharmacol. (1985) [Pubmed]
  8. Carotid arterial hemodynamics in hypertension: acute administration of captopril or cadralazine. Lacolley, P.J., Laurent, S.T., Billaud, E.B., Safar, M.E. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. (1989) [Pubmed]
  9. Different effects of temocapril and cadralazine on electrocardiographic voltages and left ventricular mass in patients with essential hypertension. Tomita, S., Takata, M., Yasumoto, K., Tomoda, F., Ueno, H., Inoue, H. Japanese heart journal. (1999) [Pubmed]
  10. Pharmacokinetics of cadralazine in a large group of hypertensive patients chronically treated with cadralazine: advantage over a conventional study in a small group of patients. Lecaillon, J.B., Dubois, J.P., Darragon, T., Motolese, M., Racine, A., Ducret, F., Grouberman, D., Cordonnier, D., Chanard, J., Glorioso, M. Therapeutic drug monitoring. (1991) [Pubmed]
  11. Influence of acetylator status on the haemodynamic effects and pharmacokinetics of cadralazine in healthy subjects. Brunel, P., Lecaillon, J.B., Guyene, T.T., Imhof, P., Ménard, J. British journal of clinical pharmacology. (1990) [Pubmed]
  12. Hemorheologic effects of vasodilation in essential hypertension. Wysocki, M., Andersson, O.K., Persson, B., Bagge, U., Braide, M. Angiology. (1996) [Pubmed]
  13. Hemodynamic effects of cadralazine in hexamethonium treated and non-treated anesthetized dogs. Higashio, T., Tsuji, Y., Nakao, K., Sakaguchi, S., Tanaka, M. Arzneimittel-Forschung. (1988) [Pubmed]
  14. Inhibitory effects of cadralazine and its metabolite, ISF-2405, on contractions and the level of cytosolic Ca2+ in vascular smooth muscle. Mitsui, M., Nakao, K., Inukai, T., Karaki, H. Eur. J. Pharmacol. (1990) [Pubmed]
  15. Pharmacokinetics of an active cadralazine metabolite in plasma and blood vessels of spontaneously hypertensive rats. Terauchi, Y., Watari, S., Ishikawa, S., Takeyama, K., Sekine, Y., Hashimoto, M., Hayashi, T. Arzneimittel-Forschung. (1988) [Pubmed]
  16. Role of an intact endothelium in the vascular action of cadralazine and ISF2405. Buccellati, C., Dorigotti, L., Lombroso, M., Folco, G. Pharmacol. Res. (1989) [Pubmed]
  17. Drug induced acute generalized exanthematous pustulosis. Katagiri, K., Takayasu, S. J. Dermatol. (1996) [Pubmed]
  18. Synthesis and biotransformation of 3-hydrazinopyridazine drugs. Pinza, M., Pifferi, G. Farmaco (1994) [Pubmed]
  19. Cadralazine and chlorthalidone as a second-step drug with atenolol in hypertensive patients: differences in blood pressure control during exercise. Costa, F.V., Borghi, C., Mussi, A., Ambrosioni, E. Eur. J. Clin. Pharmacol. (1986) [Pubmed]
  20. Cadralazine versus prazosin as second-step treatment in hypertensive patients on beta-blockers: a randomized multicentre study. The Italian Multicentre Study Group. Caponnetto, S., Valvo, E., Mocarelli, P., Alberti, D., Savonitto, S. Eur. J. Clin. Pharmacol. (1991) [Pubmed]
  21. The antihypertensive compounds hydralazine, dihydralazine and cadralazine and their metabolites inhibit myeloperoxidase activity as measured by chemiluminescence. Nässberger, L. Biochem. Pharmacol. (1991) [Pubmed]
  22. Effects of cadralazine on systemic blood pressure, renal function and plasma renin activity in anesthetized dogs. Yukimura, T., Miura, K., Tanaka, M., Higashio, T., Sakaguchi, S., Kuroda, K., Yamamoto, K. Arzneimittel-Forschung. (1988) [Pubmed]
  23. Determination of cadralazine in human plasma and urine by high-performance liquid chromatography. Hauffe, S.A., Dubois, J.P. J. Chromatogr. (1984) [Pubmed]
  24. Cadralazine (ISF 2469): dose-related antihypertensive activity after single oral administration to patients. Catalano, M., Parini, J., Libretti, A. Eur. J. Clin. Pharmacol. (1983) [Pubmed]
 
WikiGenes - Universities